BioSpace News Archive

Rutherrin(R) Repurposes Non-Cancer Drugs for Cancer Therapy

Theralase® Technologies Inc. is pleased to announce that in preclinical research, it’s lead drug formulation, Rutherrin® was able to repurpose non-cancer drugs for cancer therapy.

June 20, 2024
·
8 min read
SAb Biotherapeutics Rebrands as SAB BIO

SAB Biotherapeutics today announced its new name, SAB BIO, and visual identity to more closely align with its mission to treat and prevent immune and autoimmune disorders with the use of its unique immunotherapy platform.

June 20, 2024
·
5 min read
BioMidwest

Accuray and TrueNorth Medical Physics Sign Agreement to Provide Radiation Oncology Support Intended to Advance Cancer Care for More Patients

Accuray Incorporated announced an agreement with TrueNorth Medical Physics LLC to provide radiation oncology departments with third-party support designed to enhance their department’s capabilities.

June 20, 2024
·
5 min read
Drug Development

Jazz Pharmaceuticals Provides Update on Phase 2b Trial of Investigational Suvecaltamide (JZP385) in Essential Tremor

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced top-line results from the Phase 2b clinical trial (NCT05122650) evaluating the efficacy and safety of suvecaltamide (JZP385), an investigational, highly selective and state-dependent modulator of T-type calcium channels, in adult patients with essential tremor (ET).

June 20, 2024
·
6 min read
Drug Development

Spinogenix Announces Approval from the Australia Human Research Ethics Committee to Initiate a Phase 2 Human Clinical Trial of SPG302 for the Treatment of Alzheimer’s Disease

Spinogenix, Inc. today announced that the initiation of Spinogenix’s Phase 2 trial to evaluate SPG302 for the treatment of adult participants with mild-to-moderate Alzheimer’s disease (AD) was approved in Australia.

June 20, 2024
·
3 min read
Drug Development

Tempest Unveils New Survival Data for Amezalpat (TPST-1120) in Randomized First-Line HCC Study Demonstrating a Six-Month Improvement over Control Arm

Tempest Therapeutics, Inc. announced new positive data from the ongoing global randomized Phase 1b/2 clinical study in which amezalpat2, Tempest’s PPAR⍺ antagonist, delivered a six-month improvement in median overall survival advantage when combined with atezolizumab and bevacizumab in a comparison to atezolizumab and bevacizumab alone in the first-line treatment of patients with unresectable or metastatic hepatocellular carcinoma.

June 20, 2024
·
9 min read
Drug Development

New Broad-Spectrum Antiviral Currently in a Phase 2a Clinical Trial in Influenza A may be Effective Against the H5N1 Avian Influenza Strain Identified in Humans Exposed to Infected Dairy Cows

Cocrystal Pharma, Inc.’s novel, broad-spectrum antiviral CC-42344 inhibits activity in the highly pathogenic avian influenza A PB2 protein recently identified in infected dairy cattle, according to recently completed in vitro studies.

June 20, 2024
·
6 min read
Pharm Country

Tonix Pharmaceuticals Announces Positive Pre-NDA CMC Meeting with FDA for Tonmya™ for the Management of Fibromyalgia

Tonix Pharmaceuticals Holding Corp. today announced receipt of the formal minutes from a recent pre-New Drug Application (NDA) Type-B Chemistry, Manufacturing, and Controls (CMC) meeting with the U.S. Food and Drug Administration (FDA) for Tonmya™ for the management of fibromyalgia.

June 20, 2024
·
7 min read
Business

AbbVie Appoints Roxanne S. Austin as Lead Independent Director of the Board of Directors

AbbVie (NYSE: ABBV) today announced that the independent directors of the board have selected Roxanne S. Austin as lead independent director, effective July 1, 2024.

June 20, 2024
·
4 min read
Business

Regel Therapeutics Appoints Stephen J. Farr as New Chief Executive Officer

The Board of Directors of Regel Therapeutics announced that Stephen J. Farr , PhD, begins today as Chief Executive Officer (CEO).

June 20, 2024
·
2 min read